Targeted alpha therapy for recurrent high-grade glioma with [²²⁵Ac]-PSMA: a new theranostic approach
European Journal of Nuclear Medicine and Molecular Imaging · 2026-11 · 53 (13) · 8661-8674
DOI: 10.1007/s00259-026-08194-6 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, online erschienen am 21.09.2026. Verfasst von Haluk Burcak Sayman und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Istanbul, Türkiye. hbsayman@yahoo.com. Hauptthemen laut MEDLINE: Actinium, Alpha Particles, Glioma, Brain Neoplasms. Die Arbeit nennt 40 Literaturangaben.
Abstract (Originalsprache)
PURPOSE: To evaluate the feasibility, safety, and preliminary efficacy of systemic targeted alpha therapy with [²²⁵Ac]-PSMA in patients with recurrent high-grade glioma (HGG). Glioblastoma multiforme (GBM) and HGGs are highly aggressive primary brain tumors with limited treatment options at recurrence. Expression of prostate-specific membrane antigen (PSMA) in the neovasculature of GBM provides a promising target for radioligand therapy using alpha emitters such as Actinium-225. METHODS: Four patients with histologically confirmed recurrent HGG received [²²⁵Ac]-PSMA therapy at a dose of 100 kBq/kg per cycle. Diagnoses were established according to the WHO classification available at the time of diagnosis. The cohort included three patients with GBM and one patient with a high-grade diffuse glial tumor, WHO grade III. Treatment cycles were intended at 8-12-week intervals. Baseline and follow-up assessments were performed visually and then semi-quantitave parameters were described on [⁶⁸Ga]-PSMA PET/MRI or PET/CT images also using contrast-enhanced MRI. Clinical status and hematologic parameters were monitored throughout therapy and follow-up. RESULTS: While every patient ultimately developed progressive disease following treatment, the predefined PSMA-avid index lesion regressed in one patient and remained stable in another. No grade ≥ 3 adverse events attributable to [²²⁵Ac]-PSMA or treatment-related mortality were observed. Low-grade toxicity was limited and mainly consisted of mild xerostomia. CONCLUSION: Systemic [²²⁵Ac]-PSMA therapy appeared feasible and well tolerated, showing preliminary evidence of disease control in recurrent HGGs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Istanbul, Türkiye. hbsayman@yahoo.com.
- Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Campus, Kocamustafapaşa Street No: 53, 34098, Cerrahpaşa, Fatih, Istanbul, Türkiye. hbsayman@yahoo.com.
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, USA.
- Department of Radiation Oncology, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Istanbul, Türkiye.
- Department of Nuclear Medicine, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Istanbul, Türkiye.
- Department of Nuclear Medicine, University of Health Sciences Turkey, Basaksehir Cam and Sakura City Hospital, Istanbul, Türkiye.
Zitieren
APA
Sayman, H. B., Aras, O., Hekim, M. V., Sağlam, K., Akgün, E., & Dinçbaş, F. Ö. (2026). Targeted alpha therapy for recurrent high-grade glioma with [²²⁵Ac]-PSMA: a new theranostic approach. European Journal of Nuclear Medicine and Molecular Imaging, 53(13), 8661-8674. https://doi.org/10.1007/s00259-026-08194-6
Vancouver
Sayman HB, Aras O, Hekim MV, Sağlam K, Akgün E, Dinçbaş FÖ. Targeted alpha therapy for recurrent high-grade glioma with [²²⁵Ac]-PSMA: a new theranostic approach. European Journal of Nuclear Medicine and Molecular Imaging. 2026;53(13):8661-8674. doi:10.1007/s00259-026-08194-6
BibTeX
@article{Sayman2026,
author = {Sayman, Haluk Burcak and Aras, Omer and Hekim, Muhammed Veysel and Sağlam, Kerem and Akgün, Elife and Dinçbaş, Fazilet Öner},
title = {Targeted alpha therapy for recurrent high-grade glioma with [²²⁵Ac]-PSMA: a new theranostic approach},
journal = {European Journal of Nuclear Medicine and Molecular Imaging},
year = {2026},
volume = {53},
number = {13},
pages = {8661--8674},
doi = {10.1007/s00259-026-08194-6}
}
EUVIMED